Business
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026
IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant will provide further updates on this program in the second half of calendar year 2026IMVT-1402 proof-of-concept trial in cutaneous lupus erythematosus (CLE) fully enrolled with topline data expected in the second half of calendar year 2026All other clinical development timelines remain on
About this update from Immunovant, Inc.
[{"type":"image","alt":"Immunovant Inc.","displaySize":"","headline":null,"caption":"Immunovant Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":200,"height":32,"url":"https://media.zenfs.com/en/globenewswire.com/d82fe53a8399bc9c522ea1269d40b006"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1hrQcEI6UMKjyGEJx5MvqA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTU4/https://media.zenfs.com/en/globenewswire.com/d82fe53a8399bc9c522ea1269d40b006","width":200,"height":32},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/1hrQcEI6UMKjyGEJx5MvqA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTU4/https://media.zenfs.com/en/globenewswire.com/d82fe53a8399bc9c522ea1269d40b006","width":200,"height":32}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant will provide further updates on this program in the second half of calendar year 2026","length":296,"tagName":"p"}]},{"val":[{"type":"text","content":"IMVT-1402 proof-of-concept trial in cutaneous lupus erythematosus (CLE) fully enrolled with topline data expected in the second half of calendar year 2026","length":154,"tagName":"p"}]},{"val":[{"type":"text","content":"All other clinical development timelines remain on track for IMVT-1402, including potentially registrational studies in Graves’ disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP) and Sjögren’s disease (SjD)","length":250,"tagName":"p"}]},{"val":[{"type":"text","content":"Current cash balance provides runway to the potential launch of IMVT-1402 in GD","length":79,"tagName":"p"}]},{"val":[{"type":"text","content":"Roivant will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, May 20, 2026, to discuss these updates","length":121,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":900,"olType":false},{"type":"text","content":"DURHAM, N.C., May 20, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fourth quarter and fiscal year ended March 31, 2026.","length":308,"...